Cancer, Advanced
Conditions
Brief summary
This study will evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of MK0683 in patients with advanced cancer.
Interventions
DRUGvorinostat (MK0683 )
Panel A: vorinostat 400 mg capsules once daily on Days 1, 5, 7-28 Total treatment period is 28 days
Sponsors
Merck Sharp & Dohme LLC
Study design
Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Patients 18 years or older * Must agree to consume high fat meal and agree to fasting conditions * Limit alcohol consumption
Exclusion criteria
* Patient has a history of drug or alcohol abuse within 5 years of start of study * Patient is known to have HIV * Patient has participated in another investigational study within 4 weeks of start of study * Patient cannot stop taking certain medications or herbal remedies * Patient will require immunologic, radiation, surgery, or chemotherapy during the study * Patient requires frequent blood transfusions * Female patient is pregnant or nursing * Patient has an active Hepatitis B or C infection
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Safety, tolerability, and PK of MK0683 | 28 Days |
Secondary
| Measure | Time frame |
|---|---|
| Urinary excretion of MK0683 | 28 days |
Outcome results
None listed